The U.S. Preventive Services Task Force (USPSTF) commissioned this review to inform the upcoming update of its recommendation on postmenopausal hormone therapy for the primary prevention of chronic conditions. Among 9 trials that met inclusion criteria, estrogen plus progestin and estrogen alone decreased risk for fractures but increased risk for stroke, thromboembolic events, gallbladder disease, and urinary incontinence. Estrogen plus progestin increased risk for breast cancer and probable dementia, whereas estrogen alone decreased risk for breast cancer.
Topics:
primary prevention, progestins, hormone replacement therapy, menopause, preventive medicine, estrogen, chronic disease, ...
Ann Intern Med. 2012;157(2):104-113. doi:10.7326/0003-4819-157-2-201207170-00466